Alivus Life Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹682 Cr +16% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
AL

Alivus Life

Q2 FY26Pharmaceuticals & Biotechnology

Alivus Life Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹588Cr
+16% YoY
−2.3% QoQ
Net profit
₹130Cr
+36.8% YoY
+6.6% QoQ
Margin
30%
+3 pp YoY
+1 pp QoQ
Price₹1,348
Market cap₹16.6K Cr
P/E26.7

The short version

The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half. Alivus Life Sciences expects steady growth in FY '26 driven by strong demand momentum and improved visibility for the second half.

From Alivus Life's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half.
  • Non-GPL business grew by ~40% driven by successful new product launches; outlook remains strong.
  • Anticipated rebound in GPL business in the second half of FY '26.
  • CDMO segment expected to show a meaningful turnaround in H2 FY '26 with five projects ramping up.
  • Japan market to see new commercial launches, with 8-9 products going commercial, up from 4 previously, expecting 4 new molecules launched annually.
  • Broad-based growth expected from emerging markets, LATAM, Japan, Europe, and India.

2 more points from Alivus Life's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Alivus Life said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores.
  • Board-approved capex budget for FY '26 is INR600 crores, including INR190 crores carryover from FY '25.
  • Capex slowed in H1; R&D center spend is half the planned INR90-100 crores for FY '26, causing some delay.
  • Planned capex spend for H2 FY '26 is around INR250 crores.
  • Capacity expansion projects at Solapur, Ankleshwar, and Dahej are progressing well and on track.
  • Ankleshwar projects to be operational by June 2026 (Q2 FY '27).
  • Dahej projects expected operational from Q1 FY '27.
  • Solapur facility targeted to start from April next year.

2 more points from Alivus Life's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Alivus Life said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some related insights are: - The CDMO business has a healthy pipeline with 586 DMF and CEP filings globally as of September 30, 2025. - There are 26 high-potent API products in the active development grid, representing a $66 billion addressable market. - The company is confident of a meaningful turnaround in the CDMO segment in H2 FY '26 due to new projects and ramp-up of existing projects. - The outlook for GPL business is positive with expected improvement in the second half of FY '26.

2 more points from Alivus Life's call on order book

Create a free account to keep reading this call

Alivus Life — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Alivus Life Q2 FY26 results — key figures

Alivus Life Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue588507+16%602-2.3%
Operating profit (EBITDA)179134+33.6%172+4.1%
Operating margin30%27%+3 pp29%+1 pp
Profit before tax174127+37%163+6.7%
Net profit (PAT)13095+36.8%122+6.6%
EPS (₹)10.607.78+36.2%9.91+7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹682 Cr, net profit ₹197 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Alivus Life and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Alivus Life Q2 FY26 results?

The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half. Alivus Life Sciences expects steady growth in FY '26 driven by strong demand momentum and improved visibility for the second half.

What is Alivus Life share price analysis?

Alivus Life currently shows a neutral. The stock trades at a P/E of 26.7 with a market cap of ₹16,585 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alivus Life planning capital expenditure?

Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores.

Keep Alivus Life on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.